At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 10, 2026 at 15:50 ET
Exicure agreed to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million) in cash. The deal includes the license agreement, contracts, IP, clinical data and equipment, while Exicure retains its subsidiary GPCR USA and all pre-September 1, 2026 liabilities. The transaction is subject to closing conditions including a GPCR waiver and potential stockholder approval, and is part of Exicure's strategic alternatives review.
- Aggregate purchase price of KRW 6.5 billion (approximately US$4.8 million), payable entirely in cash
- KRW 500 million deposit already paid; KRW 2.0 billion due on or before November 16, 2026; KRW 4.0 billion due at closing
- Closing date is November 30, 2026, subject to satisfaction of conditions including GPCR waiver and release, regulatory approvals, third-party consents, and any required stockholder approval
- GPCR USA remains a wholly owned subsidiary of Exicure after closing; no equity interests are being transferred
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access